 Notes from the East
Woods musings on opportunities in the life science
marketplace
August 2008
|
|
|
|
Greetings!
|
This month we take a look at moving outside of the comfortable confines of the current market, and how square hockey pucks are as good as round ones. Please have a read and feel free to let me know what you think. Thanks and enjoy the dog days of summer.
Regards,
Paul Danis Founder and Principal
|
|
|
|
|
|
| Square Hockey Pucks and New Markets |
It always amazes me how kids
can take a product (e.g. building block) expressly designed for a particular
purpose and use it very successfully in an entirely unintended fashion (street hockey
puck). This approach should readily expand the size of the
markets for many kids' products. Similarly it seems
to make sense that you could easily expand the market for your current products
by simply selling them to new types of customers.
Indeed taking products to
new market segments is a very effective way to grow and is utilized by many
companies. It has a lot of appeal since
R&D costs are usually low, time to market is relatively quick, and getting
additional revenue from a sunk investment yields a very nice return. The appeal is pretty overwhelming. However, capitalizing on this opportunity is
not a downhill ride; there are some hills to climb along the way. In order to effectively win business in the
new segment there are a few areas that must be carefully analyzed and
understood.
- It is likely that your customers are far more
discerning than the kids who are quite happy with the square hockey
puck. Not unlike embarking on a new
product development program, going to a new segment requires a similar
amount of market analysis to be sure that the customers' problems will be
well served by the product. Ultimately
it comes down to answering two simple questions [with not necessarily
simple answers]: who will buy the product and why?
- Another important question is, of course, are
there enough customers to justify my effort and investment. This is a pretty straight forward
exercise with the exception of determining whether or not they will buy.
- Given the compelling reasons to move to the new
market, you must be careful to avoid the forced-fit approach. It is well worth the time to be sure the
product really solves an important problem.
- A major consideration in getting to the new
segment is the amount of product change and weighing this against building a whole
new product. This is often a
challenging area since incremental changes to the current product will
often garner some customers in the new segment. However, these are often customers more comfortable
with newer technology, and do not represent the bulk of the opportunity. Just like the forensic analyzer sold to
the FBI is a different beast than the same instrument used for basic
research at UCLA, there are almost always some product modifications
needed.
- The final area to consider is how well the new
market fits with the current sales and distribution processes of the
company. FAO Schwarz is quite good
at selling building blocks to the parents of toddlers, but would be hard-pressed to sell street
hockey equipment to teenagers. If the new
segment is adjacent to the current markets, and shares many of the same
attributes, customer types, and influence centers, then the organization
should be able to be successful there.
If, however, the new segment has a different culture, new players, and
unique influencers then the risk is significantly higher and it will
require more time to succeed.
Whether your current product
is a slam dunk into the new segment, or you are wresting with whether the stretch
is too far, taking current products to new segment is a very valuable growth
strategy. Given a good dose of
discipline the right choices can be made, and a whole new channel of sales can
be developed quickly and with minimal investment.
|
Life Science Market Update
|
|
Index
|
July Value
|
Change YTD
|
Yearly High
|
Yearly Low
|
|
EC BioTools
|
760
|
-2%
|
802
|
744
|
|
EC BigPharma
|
761
|
0%
|
764
|
745
|
|
EC Biotech
|
726
|
5%
|
726
|
641
|
Many of the life science
indices currently available are a mixture of various types of companies. In
order to better assess the situation in the different segments, Eastwoods
Consulting has created these price-weighted indices for the sectors of large
pharmaceutical companies, biotech companies, and life science research tools
companies.
-
EC BioTools Index - A, ABI, ACCL, AFFX, BEC, BIO, BRKR,
CALP, DNEX, HBIO, HLCS, ILMN, IVGN (2:1 split in June), LMNX, PKI, QGEN, SIAL,
TMO, VARI, WAT
-
EC BigPharma Index - JNJ, PFE, GSK, NVS, SNY, MRK, ABT,
LLY, AZN, WYE, BMY, NVO, BAX, TEVA, SGP, RHHBY.PK
-
EB Biotech Index - DNA, AMGN, GENZ, BIIB, CEPH, GILD,
BMRN, AMLN, IDXX, SEPR, OSIP, PDLI, CPHD, ALKS, REGN, MEDX, THRX, HGSI, SGMO,
ENZN, NKTR
-
Prices are
taken at the close of each month.
|
|
| About Eastwoods Consulting
|
Eastwoods Consulting helps companies connect their technologies and products with the life science marketplace. By focusing on the most valuable opportunities, efficiency is increased, and profits grow.
|
Copyright © 2008, Eastwoods Consulting. This
publication may be freely redistributed in full or in part as long as full
attribution and our contact information, including email address, telephone
number, and web address, are included.
|
|
|
|
|